Online citations, reference lists, and bibliographies.
Referencing for people who value simplicity, privacy, and speed.
Get Citationsy
← Back to Search

Prostatic 25‐hydroxyvitamin D‐1α‐hydroxylase And Its Implication In Prostate Cancer

Tai C. Chen, Lilin Wang, Lyman W. Whitlatch, J. Flanagan, M. Holick
Published 2003 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Evidence suggests that vitamin D may have a protective role for prostate cancer. 1α,25‐Dihydroxyvitamin D [1α,25(OH)2D] inhibits growth and induces differentiation of prostate cells. 25‐Hydroxyvitamin D‐1α‐hydroxylase [1α‐OHase], the enzyme that is responsible for the synthesis of 1α,25(OH)2D, is expressed in cultured prostate cells. We observed a marked decrease in 1α‐OHase activity in prostate cancer cells, suggesting some defect of the 1α‐OHase in these cells. To investigate whether the defect was due to dysregulation of the enzyme at the promoter level, a series of deletion constructs of the promoter was synthesized and incorporated upstream into the luciferase reporter gene. Two regions were identified with high basal activity in transfected normal prostate cell line (PZHPV‐7), −1100 bp (AN2), and −394 bp (AN5) upstream of ATG start site of the 1α‐OHase gene. When the reporter gene with either AN2 or AN5 was transfected into prostate cancer cell lines, we observed a lower basal promoter activity in PC‐3 cells and DU145 cells than that found in PZHPV‐7 cells for both constructs, and a loss of promoter activity in LNCaP cells. Thus, the results suggest that the defect in enzyme activity may result from the decreased promoter activity in prostate cancer cells. J. Cell. Biochem. 88: 315–322, 2003. © 2002 Wiley‐Liss, Inc.
This paper references
Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1.
G. K. Fu (1997)
25-Hydroxyvitamin D-1α-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer
L. Whitlatch (2002)
Molecular cloning, characterization, and promoter analysis of the human 25-hydroxhvitamin
XF Kong (1999)
The in Vitro Evaluation of 25-Hydroxyvitamin D3 and 19-nor-1a,25-
T. Chen (2000)
Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis).
G. G. Schwartz (1990)
Liarozole Acts Synergistically with 1α,25-Dihydroxyvitamin D3 to Inhibit Growth of DU 145 Human Prostate Cancer Cells by Blocking 24-Hydroxylase Activity.
L. H. Ly (1999)
The 25‐Hydroxyvitamin D 1‐Alpha‐Hydroxylase Gene Maps to the Pseudovitamin D‐Deficiency Rickets (PDDR) Disease Locus
R. St-Arnaud (1997)
Molecular cloning, characterization, and promoter analysis of the human 25-hydroxyvitamin D3-1alpha-hydroxylase gene.
X. Kong (1999)
Molecular cloning , characterization , and promoter analysis of the human 25 - hydroxhvitamin D 3 - 1 a - hydroxylase gene
XF Kong (1999)
Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells.
D. Peehl (1994)
25-Hydroxyvitamin D3 1α-Hydroxylase and Vitamin D Synthesis
Ken-ichi Takeyama (1997)
Expression and regulation of 25-hydroxyvitamin D3-1-alphahydroxylase in cultured human prostatic cells
TC Chen (1998)
The antiproliferative and differentiative activities of 1,25-dihydroxyvitamin D3 are potentiated by epidermal growth factor and attenuated by insulin in cultured human keratinocytes.
T. Chen (1995)
Human prostate cancer cells: inhibition of proliferation by vitamin D analogs.
G. G. Schwartz (1994)
Vitamin D: Photobiology, metabolism, and clinical applications
Holick MF. (1995)
Liarozole acts synergistically with 1,25-dihydroxyvitamin D3 to inhibit DU-145 human prostate cancer cell growth by blocking 24-hydroxylase activity
XY Zhao (1999)
Parathyroid hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter.
H. Brenza (1998)
Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines.
R. Skowroński (1993)
The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3.
G. Miller (1992)
Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3.
G. G. Schwartz (1998)
The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
T. Chen (2000)
Characterization of primary cell cultures derived from rat renal proximal tubules.
T. Chen (1989)
Human prostate cells
GG Schwartz (1998)
Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol)
C. Gross (1998)
Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
R. Skowroński (1995)
Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition.
J. Y. Hsu (2001)
Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)
M. Ahonen (2004)
Extrarenal production of calcitriol.
A. Dusso (1990)
Antiproliferative Effect of 1α,25-Dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-Dependent Kinase 2 Activity and Persistent G1 Accumulation.
S. Zhuang (1998)
Human prostate cancer cells: inhibition of proliferation by vitamin D analogs.
Schwartz Gg (1994)
Neonatal human foreskin keratinocytes produce 1,25-dihydroxyvitamin D3.
D. Bikle (1986)
Current understanding of the molecular actions of vitamin D.
G. Jones (1998)
Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer.
J. Osborn (1995)
Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians.
J. Ma (1998)

This paper is referenced by
Vitamin D and prostate cancer risk--a less sunny outlook?
L. Mucci (2008)
The vitamin D and cancer conundrum: aiming at a moving target.
Cheryl D. Toner (2010)
Vitamin D and cancer: clinical aspects.
A. Woloszynska-Read (2011)
Vitamin D: Biology, Actions, and Clinical Implications
D. Feldman (2001)
Role of oncoprotein Growth Factor Independent-1 (GFI1) in repression of 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1): A comparative analysis in human prostate cancer and kidney cells
P. Dwivedi (2007)
25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D.
G. Jones (2012)
Evidence for auto/paracrine actions of vitamin D in bone: 1a‐hydroxylase expression and activity in human bone cells
M. Driel (2006)
Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer
A. Krishnan (2007)
1α,25-Dihydroxyvitamin D3 downregulates CYP27B1 and induces CYP24A1 in colon cells
D. Lechner (2007)
25 hydroxy-vitamin D3-1α hydroxylase expression and activity in cultured human osteoblasts and their modulation by parathyroid hormone, estrogenic compounds and dihydrotestosterone
D. Somjen (2007)
25‐Hydroxyvitamin D3 is an active hormone in human primary prostatic stromal cells
Yan-Ru Lou (2004)
Extrarenal 1α-Hydroxylase
M. Hewison (2011)
Calcitriol as a Chemopreventive and Therapeutic Agent in Prostate Cancer: Role of Anti‐Inflammatory Activity
A. Krishnan (2007)
Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol)
M. Maggi (2006)
Vitamin D and breast cancer.
E. Bertone-Johnson (2009)
Anti-inflammatory Activity of Calcitriol That Contributes to Its Therapeutic and Chemopreventive Effects in Prostate Cancer
A. Krishnan (2010)
The Role of Vitamin D in the Prevention and Treatment of Prostate Cancer
S. Maund (2011)
Expression of the Vitamin D Receptor Is Increased in the Hypertrophic Heart
S. Chen (2008)
Symposium on ‘ Diet and cancer ’ The vitamin D receptor in cancer
James L. Thorne (2008)
Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol)
L. Adorini (2007)
Mutual interaction of special phytoestrogenic compounds, their synthetic carboxy-derivatives and the less-calcemic vitamin D analog activities in human derived female cultured osteoblasts
D. Somjen (2011)
Vitamin D 3 metabolism in normal and malignant human prostate cells
Yan-Ru Lou (2005)
Vitamin D and Cancer Chemoprevention
J. Fleet (2010)
Vitamin D Signaling Modulators in Cancer Therapy.
W. Luo (2016)
Associations of circulating 25‐hydroxyvitamin D with prostate cancer diagnosis, stage and grade
R. Gilbert (2012)
CHAPTER 94 – Vitamin D and Prostate Cancer
A. Krishnan (2005)
Fifth International Symposium on the Role of Soy in Preventing and Treating Chronic Disease
R. Merritt (2004)
Vitamin D metabolism and action in the prostate: Implications for health and disease
S. Swami (2011)
Clinical Nutrition for Oncology Patients
M. Marian (2009)
Vitamin D and cancer incidence in the Harvard cohorts.
E. Giovannucci (2009)
CYP24A1 Expression Inversely Correlates with Melanoma Progression: Clinic-Pathological Studies
A. Brożyna (2014)
Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer.
M. McCullough (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar